PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Top Cited Papers
- 2 July 2015
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 28 (1), 70-81
- https://doi.org/10.1016/j.ccell.2015.05.010
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Combined targeting of HER2 and VEGFR2 for effective treatment ofHER2-amplified breast cancer brain metastasesProceedings of the National Academy of Sciences, 2012
- Acquired resistance to drugs targeting receptor tyrosine kinasesBiochemical Pharmacology, 2012
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsCancer Research, 2011
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record TimeCancer Cell, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010